March 2026
1. RIVERA S, Ghodssighassemabadi R, Auzac G, Brion T, et al
   5-year results of hypofractionated locoregional radiotherapy in early breast cancer HypoG-01 (UNICANCER): a French multicentre, randomised, non-inferiority, phase 3, open-label, controlled trial.
   Lancet. 2026;407:976-987.
   

   >> Share

   
   
2. COLES CE, Chatterjee S, Haviland JS
   Hypofractionated nodal radiotherapy in breast cancer: time for an updated standard of care?
   Lancet. 2026;407:920-921.
   

   >> Share

   
   February 2026
3. HARADA-SHOJI N, Suzuki A, Ishida T, Yamamoto S, et al
   Cumulative incidence of advanced breast cancer in women aged 40-49 years in the Japan Strategic Anti-cancer Randomised Trial (J-START) of adjunctive ultrasonography: a prespecified secondary analysis.
   Lancet. 2026;407:784-793.
   

   >> Share

   
   January 2026
4. GOMMERS J, Hernstrom V, Josefsson V, Sartor H, et al
   Interval cancer, sensitivity, and specificity comparing AI-supported mammography screening with standard double reading without AI in the MASAI study: a randomised, controlled, non-inferiority, single-blinded, population-based, screening-accuracy tria
   Lancet. 2026;407:505-514.
   

   >> Share

   
   
5. SUSUMAN AS, Ramangoele T, Petros L, Dhludhlu K, et al
   Extended aromatase inhibitor therapy for early breast cancer.
   Lancet. 2026;407:495.
   

   >> Share

   
   
6. BRAYBROOKE J, Bradley R, Hills R
   Extended aromatase inhibitor therapy for early breast cancer - Authors' reply.
   Lancet. 2026;407:495-496.
   

   >> Share

   
   
7. KRISHNAN A, Mukherjee D
   Extended aromatase inhibitor therapy for early breast cancer.
   Lancet. 2026;407:494-495.
   

   >> Share

   
   
8. MARINOVICH ML, Houssami N
   AI for enhancing efficiency and effectiveness of population breast cancer screening.
   Lancet. 2026;407:471-473.
   

   >> Share

   
   October 2025
9. ALLEMANI C, Minicozzi P, Morawski B, Lima CA, et al
   Global variation in patterns of care and time to initial treatment for breast, cervical, and ovarian cancer from 2015 to 2018 (VENUSCANCER): a secondary analysis of individual records for 275 792 women from 103 population-based cancer registries in 39
   Lancet. 2025 Oct 22:S0140-6736(25)01383-2. doi: 10.1016/S0140-6736(25)01383.
   

   >> Share

   
   August 2025
10. 
    Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with at least 5 years of endocrine therapy.
    Lancet. 2025;406:603-614.
    

    >> Share

    
    
11. HOWELL SJ, Palmieri C
    Extending aromatase inhibitor treatment in early breast cancer; longer is better for many.
    Lancet. 2025;406:573-575.
    

    >> Share

    
    
12. BRAIN E, Mir O, Bourbouloux E, Rigal O, et al
    Adjuvant chemotherapy and hormonotherapy versus adjuvant hormonotherapy alone for women aged 70 years and older with high-risk breast cancer based on the genomic grade index (ASTER 70s): a randomised phase 3 trial.
    Lancet. 2025;406:489-500.
    

    >> Share

    
    
13. LINN SC, Hilbers FS
    Balancing quality and quantity of life in older patients with breast cancer.
    Lancet. 2025;406:422-424.
    

    >> Share

    
    May 2025
14. GILBERT FJ, Payne NR, Allajbeu I, Yit L, et al
    Comparison of supplemental breast cancer imaging techniques-interim results from the BRAID randomised controlled trial.
    Lancet. 2025 May 21:S0140-6736(25)00582-3. doi: 10.1016/S0140-6736(25)00582.
    

    >> Share

    
    
15. HOUSSAMI N
    Breast cancer screening at a crossroads: supplemental imaging for dense breasts.
    Lancet. 2025 May 21:S0140-6736(25)00803-7. doi: 10.1016/S0140-6736(25)00803.
    

    >> Share

    
    March 2025
16. PEREZ-GARCIA JM, Gebhart G, Rodriguez-Morato J, Llombart-Cussac A, et al
    Neoadjuvant therapy in HER2-positive breast cancer and interim PET - Authors' reply.
    Lancet. 2025;405:1055-1056.
    

    >> Share

    
    
17. HINDIE E, Groheux D
    Neoadjuvant therapy in HER2-positive breast cancer and interim PET.
    Lancet. 2025;405:1054-1055.
    

    >> Share

    
    February 2025
18. DUNN JA, Donnelly P, Elbeltagi N, Marshall A, et al
    Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): a multicentre, randomised, phase 3, non-inferiority trial.
    Lancet. 2025;405:396-407.
    

    >> Share

    
    
19. MANN RM
    Rethinking surveillance after breast cancer.
    Lancet. 2025;405:356-358.
    

    >> Share

    
    October 2024
20. 
    Reductions in recurrence in women with early breast cancer entering clinical trials between 1990 and 2009: a pooled analysis of 155 746 women in 151 trials.
    Lancet. 2024;404:1407-1418.
    

    >> Share

    
    
21. TARANTINO P, Tolaney SM
    Progress in breast cancer management.
    Lancet. 2024;404:1376-1378.
    

    >> Share

    
    August 2024
22. MANN GB, Rose AK, Zdenkowski N
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial - Authors' reply.
    Lancet. 2024;404:526.
    

    >> Share

    
    
23. KUNKLER I, Cameron D, Dixon M, Williams L, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:525.
    

    >> Share

    
    
24. SWANICK CW, Kelly P, Dvorak T, Mamounas EP, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:525-526.
    

    >> Share

    
    
25. MO DC, Huang JF, Luo PH, Wang HL, et al
    Adjuvant radiotherapy omission in early breast cancer: the PROSPECT trial.
    Lancet. 2024;404:524-525.
    

    >> Share

    
    July 2024
26. RUGO HS, Bardia A, Tolaney S
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial - Authors' reply.
    Lancet. 2024;404:339-340.
    

    >> Share

    
    
27. HARADA K, Ozaki A, Tanimoto T
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:339.
    

    >> Share

    
    
28. MESSORI A
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:338-339.
    

    >> Share

    
    
29. GU Y
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:338.
    

    >> Share

    
    
30. ERGUN Y
    Sacituzumab govitecan for metastatic breast cancer: the TROPiCS-02 trial.
    Lancet. 2024;404:337-338.
    

    >> Share

    
    June 2024
31. DELALOGE S, Khan SA, Wesseling J, Whelan T, et al
    Ductal carcinoma in situ of the breast: finding the balance between overtreatment and undertreatment.
    Lancet. 2024;403:2734-2746.
    

    >> Share

    
    May 2024
32. PRASAD A
    Miriam Mutebi: transforming breast cancer care in Africa.
    Lancet. 2024;403:1975.
    

    >> Share

    
    
33. COLES CE, Haviland JS, Kirby AM, Griffin C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial - Authors' reply.
    Lancet. 2024;403:1752.
    

    >> Share

    
    
34. GREGUCCI F, Ciabattoni A
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751-1752.
    

    >> Share

    
    
35. MULLIEZ T, De Ridder M
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1751.
    

    >> Share

    
    
36. GUINOT JL, Gutierrez C, Hannoun-Levi JM
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1750-1751.
    

    >> Share

    
    
37. MIZUMOTO M, Oshiro Y, Sakurai H
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749-1750.
    

    >> Share

    
    
38. ZHAO D, Li Y, Qu Y, He C, et al
    Challenges for breast radiotherapy with SIB: the IMPORT HIGH trial.
    Lancet. 2024;403:1749.
    

    >> Share

    
    April 2024
39. DE SOUZA IC, Langer FW
    Post-radiation angiosarcoma of the breast in a patient with a history of invasive ductal carcinoma.
    Lancet. 2024;403:1681-1682.
    

    >> Share

    
    
40. MOODLEY J, Unger-Saldana K
    The role of racial and ethnic discrimination in breast cancer disparities.
    Lancet. 2024 Apr 12:S0140-6736(24)00699-8. doi: 10.1016/S0140-6736(24)00699.
    

    >> Share

    
    
41. COLES CE, Earl H, Anderson BO, Barrios CH, et al
    The Lancet Breast Cancer Commission.
    Lancet. 2024 Apr 12:S0140-6736(24)00747-5. doi: 10.1016/S0140-6736(24)00747.
    

    >> Share

    
    
42. SAMARASEKERA U
    Charlotte Coles: collaborating to tackle breast cancer inequities.
    Lancet. 2024 Apr 12:S0140-6736(24)00752-9. doi: 10.1016/S0140-6736(24)00752.
    

    >> Share

    
    
43. EARL HM
    Safe de-escalation of chemotherapy in HER2-positive early breast cancer.
    Lancet. 2024 Apr 3:S0140-6736(24)00535-X. doi: 10.1016/S0140-6736(24)00535.
    

    >> Share

    
    
44. PEREZ-GARCIA JM, Cortes J, Ruiz-Borrego M, Colleoni M, et al
    3-year invasive disease-free survival with chemotherapy de-escalation using an (18)F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial.
    Lancet. 2024 Apr 3:S0140-6736(24)00054-0. doi: 10.1016/S0140-6736(24)00054.
    

    >> Share

    
    March 2024
45. BRAYBROOKE J, Bradley R, Gray R, Hills R, et al
    Benefits and risks of anthracyclines in early-stage breast cancer - Authors' reply.
    Lancet. 2024;403:1240.
    

    >> Share

    
    
46. KUDE DE ALMEIDA F, Soares Falcetta F, Dornelles Rosa D
    Benefits and risks of anthracyclines in early-stage breast cancer.
    Lancet. 2024;403:1239-1240.
    

    >> Share

    
    
47. HICKEY M, Basu P, Sassarini J, Stegmann ME, et al
    Managing menopause after cancer.
    Lancet. 2024;403:984-996.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share